Abstract
For the past 30 years, since their discovery, dendritic cells (DCs) have been the focus of many studies that outline the critical role of DCs in activation and, more recently, regulation of the immune response. As will be discussed in this chapter, DCs are specialized antigen-presenting cells (APCs) that are integral to both the initiation of allograft rejection and the induction and maintenance of transplant tolerance. Both donor and recipient DCs contribute to the rejection response but it seems to be the DCs of the recipient that participate in both the acute and chronic phases of rejection. Therefore, these DCs are an ideal target for manipulation of the rejection response in favor of promoting tolerance induction. Before discussing these developing issues, we must first understand how these cells were first discovered and how we began to understand their importance in transplantation.
Keywords
- Dendritic Cell
- Dendritic Cell Subset
- Transplant Tolerance
- Mixed Leukocyte Reaction
- Tryptophan Catabolism
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Fearon, D.T. and R.M. Locksley (1996). The instructive role of innate immunity in the acquired immune response.Science272(5258), 50–54.
Akira, S., K. Takeda, and T. Kaisho (2001). Toll-like receptors: Critical proteins linking innate and acquired immunity.Nat. Immunol.2(8), 675–680.
Lipscomb, M.F. and B.J. Masten (2002). Dendritic cells: Immune regulators in health and disease.Physiol. Rev.82(1), 97–130.
Dieu-Nosjean, M. et al. (1999). Regulation of dendritic cell trafficking: A process that involves the participation of selective chemokines.J. Leuk. Biol.66, 252–262.
Gallucci, S. and P. Matzinger (2001). Danger signals: SOS to the immune system.Curr. Opin. Immunol.13(1), 114–119.
Luster, A.D. (2002). The role of chemokines in linking innate and adaptive immunity.Curr. Opin. Immunol.14, 129–135.
Sozzani, S.et al.(1998). Differential regulation of chemokine receptors during dendritic cell maturation: A model for their trafficking properties.J. Immunol.161, 1083.
Langenkamp, A.et al.(2000). Kinetics of dendritic cell activation: Impact on priming TH1, TH2 and nonpolarized T cells.Nat. Immunol.1, 311–316.
Kalinski, P.et al.(1997). IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2promote type 2 cytokine production in maturing human naive T helper cells.J. Immunol.159, 28–35.
Palucka, K. and J. Banchereau (1999). Dendritic cells: A link between innate and adaptive immunity.J. Clin. Immunol.19(1), 12–25.
Steinman, R.M. and Z.A. Cohn (1973). Identification of a novel cell type in peripheral lymphoid organs of mice.I. Morphology, quantitation, tissue distribution.J. Exp. Med.137(5), 1142–1162.
Steinman, R.M., J. Adams, and Z. Cohn (1975). Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen.J. Exp. Med.141, 804–820.
Steinman, R.M. and Z. Cohn (1974). Identification of a novel cell type in peripheral lymphoid organs of mice.II. Functional properties in vitro.J. Exp. Med.139, 380–397.
Banchereau, J., F. Briere, and C. Caux (2000). Immunobiology of dendritic cells.Annu. Rev. Immunol.18, 767.
Banchereau, J. and R.M. Steinman (1998). Dendritic cells and the control of immunity.Nature392(6673), 245–252.
Geijtenbeek, T.et al.(2000). Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses.Cell100, 575–585.
Granucci, F.et al.(2003). Early IL-2 production by mouse dendritic cells is the result of microbial-induced priming.J. Immunol.170(10), 5075–5081.
Steinman, R.M. (1991). The dendritic cell system and its role in immunogenicity.Annu Rev. Immunol.9, 271–296.
Shortman, K. and Y.-J. Liu (2002). Mouse and human dendritic cell subtypes.Nat. Rev. Immunol.2, 151–161.
Inaba, K.et al.(1993). Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow.Proc. Natl. Acad. Sci. USA90(7), 3038–3042.
Bjorck, P. and P. Kincade (1998). CD19+pro-B cells can give rise to dendritic cells in vitro.J. Immunol.161, 5795–5799.
Izon, D. (2001). A common pathway for dendritic cell and early B cell development.J. Immunol.167, 1387–1392.
Ardavin, C.et al.(1993). Thymic dendritic cells and T cells develop simultaneously within the thymus from a common precursor population.Nature362, 761–763.
Ardavin, C. and K. Shortman (1992). Cell surface marker analysis of mouse thymic dendritic cells.Eur. J. Immunol.22(3), 859–862.
Manz, M.G.et al.(2001). Dendritic cell potentials of early lymphoid and myeloid progenitors.Blood97(11), 3333–3341.
Traver, D.et al.(2000). Development of CD8alpha-positive dendritic cells from a common myeloid progenitor.Science290(5499), 2152–2154.
Wu, L.et al.(2001). Development of thymic and splenic dendritic cell populations from different hemopoietic precursors.Blood98(12), 3376–3382.
Kamath, A.et al.(2000). The development, maturation, and turnover rate of mouse spleen dendritic cell populations.J. Immunol.165, 6762–6770.
Strobl, H.et al.(1998). Identification of CD68+lin-peripheral blood cells with dendritic precursor characteristics.J. Immunol.161, 740–748.
Masten, B.J.et al.(1997). Characterization of accessory molecules in murine lung dendritic cell function: Roles for CD80, CD86, CD54, and CD40L.Am. J. Respir. Cell Mol. Biol.16(3), 335–342.
Woo, J.et al.(1994). Isolation, phenotype, and allostimulatory activity of mouse liver dendritic cells.Transplantation58(4), 484–491.
O’Connell, P.J.et al.(2000). Phenotypic and functional characterization of mouse hepatic CD8 alpha+ lymphoid-related dendritic cells.J. Immunol.165(2), 795–803.
Leenen, P.J.et al.(1998). Heterogeneity of mouse spleen dendritic cells: In vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover.J. Immunol.160, 2166–2173.
Garrigan, K.et al.(1996). Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors.Blood88(9), 3508–3512.
Martin, P.et al.(2000). Concept of lymphoid versus myeloid dendritic cell lineages revisited: Both CD8alpha(-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors.Blood96(7), 2511–2519.
Vremec, D.et al.(2000). CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen.J. Immunol.164(6), 2978–2986.
Zou, G. and Y. Tam (2002). Cytokines in the generation and maturation of dendritic cells: Recent advances.Eur. Cytokine. Netw.13(2), 186–199.
Inaba, K.et al.(1998). Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.J. Exp. Med.188(11), 2163–2173.
Sallusto, F. and A. Lanzavecchia (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage-colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor alpha. ZExp. Med.179, 1109–1118.
Romani, N.et al.(1994). Proliferating dendritic cell progenitors in human blood.J. Exp. Med.180(1), 83–93.
Chomarat, P., M. Rybak, and J. Banchereau (1998). Interleukin-4. In Angus W. Thomson and Michael T. Lotze (eds.)The Cytokine HandbookVol. 3. Elsevier Ltd, Oxford. pp. 133–174.
Quesniaux, V.F.J. and T.C. Jones, (1998). Granulocyte-macrophage colony stimulating factor. In Angus W. Thomson and Michael T. Lotze (eds.)The Cytokine HandbookVol. 3. Elsevier Ltd, Oxford. pp. 637–670.
Holgate, S. (2000). Epithelial damage and response.Clin. Exp. Allergy.30(Suppl 1), 37–41.
Metcalf, D.et al.(1987). Hemopoietic responses in mice injected with purified recombinant murine GM-CSF.Exp. Hematol.15, 1–9.
Witmer-Pack, M.D.et al.(1987). Granulocyte/macrophage colony-stimulating factor is essential for the viability and function of cultured murine epidermal Langerhans cells.J. Exp. Med.166(5), 1484–1498.
Inaba, K.et al.(1992). Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.J. Exp. Med.176(6), 1693–1702.
Caux, C.et al.(1992). GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells.Nature360(6401), 258–261.
Sallusto, F. and A Lanzavecchia (1995). Dendritic cells use macropinocytosis and the mannose receptor to concentrate antigen in the MHC class II compartment: Downregulation by cytokines and bacterial products.J. Exp. Med.182, 389.
Weigel, B.et al.(2002). Comparative analysis of murine marrow-derived dendritic cells generated by F1t3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses.Blood100(12), 4169–4176.
Gitlitz, B.et al.(2003). Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer.J. Immunother.26(2), 171–178.
Randolph, G.J.et al.(1998). Differentiation of monocytes into dendritic cells in a model of transendothelial traffickingScience282(5388), 480–483.
Dauer, M.et al.(2003). Mature dendritic cells derived from human monocytes within 48 hours: A novel strategy for dendritic cell differentiation from blood precursors.J. Immunol.170, 4069–4076.
Shurin, M.R., C. Esche, and M.T. Lotze (1998). FLT3: Receptor and ligand. Biology and potential clinical application.Cytokine Growth Factor Rev.9(1), 37–48.
Maraskovsky, E.et al.(1997). Dramatic numerical increase of functionally mature dendritic cells in FLT3 ligand-treated mice.Adv. Exp. Med. Biol.417, 33–40.
Masurier, C.et al.(1999). Immunophenotypical and functional heterogeneity of dendritic cells generated from murine bone marrow cultured with different cytokine combinations: Implications for anti-tumoral cell therapy.Immunology96(4), 569–577.
Lyman, S.et al.(1993). Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells.Cell75, 1157–1167.
Lyman, S.et al.(1994). Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells.Blood83, 2795–2801.
Lyman, S.et al.(1995). Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs.Oncogene10, 149–157.
Lyman, S.et al.(1995). Structural analysis of human and mutine flt3 ligand generated by alternative splicing of mRNAs.Oncogene11, 1165–1172.
Gabbianelli, M.et al.(1995). Multi-level effects of Flt3 ligand on human hematopoiesis: Expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors.Blood86, 1661.
Jacobsen, S.E.et al.(1996). Ability of flt3 ligand to stimulate the in vitro growth of primitive marine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-beta and tumor necrosis factor-alpha.Blood87(12), 5016–5026.
Maraskovsky, E.et al.(1996). Dramatic increase in the numbers of functionally mature dendritic cells in F1t3 ligand-treated mice: Multiple dendritic cell subpopulations identified.J. Exp. Med.184(5), 1953–1962.
Shurin, M.R.et al.(1997). FLT3 ligand induces the generation of functionally active dendritic cells in mice.Cell. Immunol.179(2), 174–184.
Pulendran, B.et al.(1997). Developmental pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice.J. Immunol.159(5), 2222–2231.
O’Keeffe, M.et al.(2002). Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice.Blood99(6), 2122–2130.
Miller, G.et al.(2003). Murine flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties.J. Immunol.170(7), 3554–3564.
Vremec, D.et al.(1992). The surface phenotype of dendritic cells purified from mouse thymus and spleen: Investigation of the CD8 expression by a subpopulation of dendritic cells.J. Exp. Med.176(1), 47–58.
Suss, G. and K. Shortman (1996). A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis.J. Exp. Med.183, 1789–1796.
Inaba, K.et al.(1997). High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes.J. Exp. Med.186(5), 665–672.
Kronin, V.et al.(1996). A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production.J. Immunol.157, 3819–3827.
Kronin, V.et al.(1997). Are CD8+ dendritic cells (DC) veto cells? The role of CD8 on DC in DC development and in the regulation of CD4 and CD8 T cell responses.Int. Immunol.9(7), 1061–1064.
Kronin, V.et al.(2001). Differential effect of CD8(+) and CD8(-) dendritic cells in the stimulation of secondary CD4(+) T cells.Int. Immunol.13(4), 465–473.
Zamoyska, R. (1994). The CD8 coreceptor: One chain good, two chains better.Immunity1, 243–246.
Gao, G.F. and B.K. Jakobsen (2000). Molecular interactions of coreceptor CD8 and MHC class I: The molecular basis for functional coordination with the T-cell receptor.Immunol. Today21(12), 630–636.
Garcia, K.et al.(1996). CD8 enhances formation of stable T-cell receptor/MHC class I molecule complexes.Nature384, 577–581.
Kern, R.et al.(1999). Expression, purification, and functional analysis of murine ectodomain fragments of CD8aa and CD8aß dimers.J. Biol. Chem.274, 27237–27243.
Bosselut, R.et al.(2000). Role of CD813 domains in CD8 coreceptor function: Importance for MHC I binding, signaling, and positive selection of CD8+T cells in the thymus.Immunity12, 409–418.
Leishman, A.et al.(2001). T cell responses modulated through interaction between CD8aa and the nonclassical MHC class I molecule.Science294, 1936–1939.
Cella, M., E Sallusto, and A Lanzavecchia (1997). Origin, maturation and antigen presenting function of dendritic cells.Curr. Opin. Immunol.9, 10–16.
Hart, D. (1997). Dendritic cells: Unique leukocyte populations which control the primary immune response.Blood90, 3245–3287.
Coyle, A. and J. Gutierrez-Ramos (2001). The expanding B7 superfamily: Increasing complexity in costimulatory signals regulating T-cell function.Nat. Immunol.2, 203–209.
Granucci, F.et al.(2002). IL-2 mediates adjuvant effect of dendritic cells.Trends Immunol.23(4), 169–173.
Ridge, J., F.D. Rosa, and R. Matzinger (1998). A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper cell and a T-killer cell.Nature393, 474–478.
Swiggard, W.J.et al.(1995). DEC-205, a 205-kDa protein abundant on mouse dendritic cells and thymic epithelium that is detected by the monoclonal antibody NLDC-145: Purification, characterization, and N-terminal amino acid sequence.Cell. Immunol.165(2), 302–311.
Kronin, V.et al.(2000). DEC-205 as a marker of dendritic cells with regulatory effects on CD8 T cell responses.Int. Immunol.12(5), 731–735.
Winkel, K.et al.(1994). CD4 and CD8 expression by human and mouse thymic dendritic cells.Immunol. Lett.40(2), 93–99.
Grouard, G.et al.(1997). The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand.J. Exp. Med.185, 1101–1111.
Martin, P.et al.(2002). Characterization of a new subpopulation of mouse CD8alpha+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential.Blood100(2), 383–390.
Asselin-Paturel, C.et al.(2001). Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.Nat. Immunol.2, 1144.
Nakano, H., M. Yanagita, and M. Gunn (2001). CD11c+8220+Gr-1+cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells.J. Exp. Med.194, 1171.
Krug, A.et al.(2001). Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plas-macytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.Eur. J. Immunol.31(1), 3026–3037.
Smedt, T.D.et al.(1996). Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo.J. Exp. Med.184, 1413–1424.
Hochrein, H.et al.(2001). Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets.J. Immunol.166(9), 5448–5455.
O’Keeffe, M.et al.(2002). Mouse plasmacytoid cells: Long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus.J. Exp. Med.196(10), 1307–1319.
Hart, D. and J. Fabre (1981). Demonstration and characterization of Ia-positive dendritic cells in the interstitial connective tissues of rat heart and other tissues, but not brain.J. Exp. Med.154, 347–361.
Steiniger, B., J. Klempnauer, and K. Wonigeit (1984). Phenotype and histological distribution of interstitial dendritic cells in the rat pancreas, liver, heart, and kidney.Transplantation38, 169–174.
Sato, T.et al.(1998). Maturation of rat dendritic cells during intrahepatic translocation evaluated using monoclonal antibodies and electron microscopy.Cell Tissue Res.294, 503–514.
Morelli, A.E.et al.(2000). Preferential induction of Thl responses by functionally mature hepatic (CD8alphaand CD8alpha+) dendritic cells: Association with conversion from liver transplant tolerance to acute rejection.Transplantation69(12), 2647–2657.
Lian, Z.et al.(2003). Heterogeneity of dendritic cells in the mouse liver: Identification and characterization of four distinct populations.J. Immunol.170, 2323–2330.
Siegal, F. et al.(1999). The nature of the principal type I interferon-producing cells in human blood.Science284, 1835.
Bjorck, P. (2001). Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice.Blood98(13), 3520–3526.
Holt, P.G.et al.(1989). Ia-positive dendritic cells form a tightly meshed network within the human airway epithelium.Clin. Exp. Allergy19(6), 597–601.
Schon-Hegrad, M.A.et al.(1991). Studies on the density, distribution, and surface phenotype of intraepithelial class II major histocompatibility complex antigen (Ia)-bearing dendritic cells (DC) in the conducting airways.J. Exp. Med.173(6), 1345–1356.
Holt, P.G., M.A. Schon-Hegrad, and J. Oliver (1988). MHC class II antigen-bearing dendritic cells in pulmonary tissues of the rat. Regulation of antigen presentation activity by endogenous macrophage populations.J. Exp. Med.167(2), 262–274.
Holt, P.G. (2000). Antigen presentation in the lung.Am. J Respir. Crit. Care Med.162(4 Pt 2), S151–S156.
Cochand, L.et al.(1999). Human lung dendritic cells have an immature phenotype with efficient mannose receptors.Am. J. Respir. Cell Mol. Biol.21(5), 547–554.
Dodge, I.L.et al.(2003). IL-6 production by pulmonary dendritic cells impedes Thl immune responses.J. Immunol.170, 4457–4464.
Valdez, Y.et al.(2002). Major histocompatibility complex class II presentation of cell-associated antigen is mediated by CD8alpha+ dendritic cells in vivo.J. Exp. Med.195(6), 683–694.
Julia, V.et al.(2002). A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cell long after antigen exposure.Immunity16(2), 271–283.
van Rijt, L.S.et al.(2002). Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD3lhiLy-6Cneg bone marrow precursors in a mouse model of asthma.Blood100(10), 3663–3671.
Holt, P.G.et al.(1994). Origin and steady-state turnover of class II MHC-bearing dendritic cells in the epithelium of the conducting airways.J. Immunol.153(1), 256–261.
Kurts, C.et al.(1997). Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells.J. Exp. Med.186, 239–245.
Huang, Y.M.et al.(2000). Autoantigen-pulsed dendritic cells induce tolerance to experimental allergic encephalomyelitis (EAE) in Lewis rats.Clin. Exp. Immunol.122(3), 437–444.
Constant, S., K. Lee, and K. Bottomly (2000). Site of antigen delivery can influence T cell priming: Pulmonary environment promotes preferential Th2-type differentiation.Eur. J. Immunol.30, 840.
Kuchroo, V.et al.(1995). B7–1 and B7–1 costimulatory molecules activate differentially the Thl/Th2 development pathways: Application to autoimmune disease therapy.Cell80, 7–1.
Straw, A.D.et al.(2003). CD154 plays a central role in regulating dendritic cell activation during infections that induce Thl or Th2 responses.J. Immunol.170(2), 727–734.
Keane-Myers, A.et al.(1997). B7–CD28/CTLA-4 costimulatory pathways are required for the development of the T helper cell 2-mediated allergic airway responses to inhaled antigens.J. Immunol.158, B7–CD28.
Sertl, K.et al.(1986). Dendritic cells with antigen-presenting capability reside in airway epithelium, lung parenchyma, and visceral pleura.J. Exp. Med.163(2), 436–451.
Gong, J.L.et al.(1992). Intraepithelial airway dendritic cells: A distinct subset of pulmonary dendritic cells obtained by microdissection.J. Exp. Med.175(3), 797–807.
Nicod, L.P., L. Cochand, and D. Dreher (2000). Antigen presentation in the lung: Dendritic cells and macrophages.Sarcoidosis Vasc. Diffuse Lung Dis.17, 246–255.
Vermaelen, K.Y.et al.(2001). Specific migratory dendritic cells rapidly transport antigen from the airways to the thoracic lymph nodes.J. Exp. Med.193(1), 51–60.
Lambrecht, B.et al.(2000). Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation.J. Clin. Invest.106, 551–559.
Geppert, T. and P. Lipsky (1987). Dissection of the antigen presenting function of tissue cells induced to express HLA-DR by gamma interferon.J. Rheumatol.14, 59–62.
Weinberg, D. and E. Unanue (1981). Antigen-presenting function of alveolar macrophages: Uptake and presentation of Listeria monocytogenes.J. Immunol.126, 794–799.
Upham, J.et al(1995). Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion.Immunology84, 142–147.
Marietta, M.et al.(1988). Macrophage oxidation of L-arginine to nitrate and nitrite: Nitric oxide is an intermediate.Biochemistry27, 8706.
Roth, M. and S. Golub (1993). Human pulmonary macrophages utilize prostaglandins and transforming growth factor betal to suppress lymphocyte activation.J. Leukoc. Biol.53, 366.
Thepen, T., G. Kraal, and P.G. Holt (1994). The role of alveolar macrophages in regulation of lung inflammation.Ann. N. Y. Acad. Sci.725, 200–206.
Boehringer, N.et al.(1999). Differential regulation of tumour necrosis factor-a (TNF-a) and interleukin-10 (IL-10) secretion by protein kinase and phosphatase inhibition in human alveolar macrophages.Eur. Cytokine Netw.10, 211–217.
Holt, P.G.et al.(1993). Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages.J. Exp. Med.177(2), 397–407.
Thepen, T., N.V. Rooijen, and G. Kraal, (1989). Alveolar macrophage elimination in vivo is associated with an increase in pulmonary immune response in mice.J. Exp. Med.170, 499–509.
Koch, F.et al.(1996). High level IL-12 production by murine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. IExp. Med.184, 741–746.
Armstrong, L.R.et al.(1994). Regulation of the immunostimulatory activity of rat pulmonary interstitial dendritic cells by cell-cell interactions and cytokines.Am. J. Respir. Cell Mol. Biol.11(6), 682–691.
Bowers, W., M. Ruhoff, and E. Goodell (1990). Conditioned medium from activated rat macrophages and the recombinant factors, IL-lb and GM-CSF, enhance the accessory activity of dendritic cells.Immunobiology180, 362–384.
Tsitoura, D.et al.(2000). Mechanisms preventing allergen-induced airways hyperreactivity: Role of tolerance and immune deviation.J. Allergy Clin. Immunol.106, 239–246.
Tsitoura, D.et al.(1999). Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. JImmunol.163, 2592–2600.
Akbari, O., R.H. DeKruyff, and D.T. Umetsu (2001). Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen.Nat. Immunol.2(8), 725–731.
Mellor, A.L. and D.H. Munn (2003). Tryptophan catabolism and regulation of adaptive immunity.J. Immunol.170(12), 5809–5813.
Constant, S.L.et al.(2002). Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ.J. Clin. Invest.110(10), 1441–1448.
Yoshida, R. and O. Hayaishi (1978). Induction of pulmonary indoleamine 2,3-dioxygenase by intraperitoneal injection of bacterial lipopolysaccharide.Proc. Natl. Acad. Sci. USA75(8), 3998–4000.
Yoshida, R.et al.(1979). Induction of indoleamine 2,3-dioxygenase in mouse lung during virus infection.Proc. Natl. Acad. Sci. USA76(8), 4084–4086.
Yoshida, R.et al.(1981). Induction of pulmonary indoleamine 2,3-dioxygenase by interferon.Proc. Natl. Acad. Sci. USA78(1), 129–132.
Urade, Y.et al.(1983). Induction of indoleamine 2,3-dioxygenase in alveolar interstitial cells of mouse lung by bacterial lipopolysaccharide.J. Biol. Chem.258(10), 6621–6627.
Swanson, K.A.et al.(2004). CD11c+ cells modulate pulmonary immune responses by production of indoleamine 2,3-dioxygenasel.Am. J. Respir. Cell Mol. Biol.30(3), 311–318.
Hayaishi, 0.et al.(1975). Indoleamine 2,3-dioxygenase. Note II. Biological function.Acta Vitaminol. Enzymol.29(1–6), 1–6.
Hirata, F., T. Ohnishi, and O. Hayaishi (1977). Indoleamine 2,3-dioxygenase. Characterization and properties of enzyme. 02-complex.J. Biol. Chem.252(13), 4637–4642.
Grohmann, U., F. Fallarino, and P. Puccetti (2003). Tolerance, DCs and tryptophan: Much ado about IDO.Trends Immunol.24(5), 242–248.
Feigelson, P., Y. Ishimura, and 0. Hayaishi (1964). On the activation and catalytic mechanism of microbial tryptophan pyrrolase.Biochem. Biophys. Res. Commun.14, 96–101.
Cook, J.S., C.I. Pogson, and S.A. Smith (1980). Indoleamine 2,3-dioxygenase. A new, rapid, sensitive radiometric assay and its application to the study of the enzyme in rat tissues.Biochem. J.189(3), 461–466.
Yamazaki, F.et al.(1985). Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme.Biochem. J.230(3), 635–638.
Kotake, Y. and T. Masayama (1937). Uber den mechanismus der kynurenin-bildung aus tryptophan.HoppeSeyler’s Z. Physiol. Chem.243, 237–244.
Knox, W. and A. Mehler (1951). The adaptive increase of the tryptophan peroxidase oxidase system of liver.Science113, 237–238.
Takikawa, O.et al.(1986). Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.J. Biol. Chem.261(8), 3648–3653.
Mellor, A.L. and D.H. Munn (1999). Tryptophan catabolism and T-cell tolerance: Immunosuppression by starvation?Immunol. Today20(10), 469–473.
Bianchi, M., R. Bertini, and R Ghezzi (1988). Induction of indoleamine dioxygenase by interferon in mice: A study with different recombinant interferons and various cytokines.Biochem. Biophys. Res. Commun.152, 237–242.
Fujigaki, S., K. Saito, K. Sekikawa, S. Tone, O. Takikawa, H. Fujiietal. (2001). Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-g-independent mechanism.Eur. J. Immunol.31, 2313–2318.
Liebau, C.et al.(2002). Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma.Anticancer Res.22(2A), 931–936.
Alberati-Giani, D., R Malherbe, P. Ricciardi-Castagnoli, C. Kohler, S. Denis-Donini, and A.M. Cesura (1997). Differential regulation of indoleamine 2,3-dioxygenase expression by nitric oxide and inflammatory mediators in IFN-gamma-activated murine macrophages and microglial cells.J. Immunol.159(1), 419–426.
Musso, T.et al.(1994). Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes.Blood83(5), 1408–1411.
MacKenzie, C.et al.(1999). Cytokine mediated regulation of interferon-gamma-induced IDO activation.Adv. Exp. Med. Biol.467, 533–539.
Yuan, W.et al.(1998). Modulation of cellular tryptophan metabolism in human fibroblasts by transforming growth factor-beta: Selective inhibition of indoleamine 2,3 dioxygenase and tryptophanyl-tRNA synthetase gene expression.J. Cell. Physiol.177(1), 174–186.
Munn, D.H.et al.(1999). Inhibition of T cell proliferation by macrophage tryptophan catabolism.J. Exp. Med.189(9), 1363–1372.
Hwu, P.et al.(2000). Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation.J. Immunol.164, 3596–3599.
Mellor, A.L., D.B. Keskin, T. Johnson, R Chandler, and D.H. Munn (2002). Cells expressing indoleamine 2,3dioxygenase inhibit T cell responses.J. Immunol.168(8), 3771–3776.
Frumento, G.et al.(2002). Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase.J. Exp. Med.196, 459–468.
Terness, P.et al.(2002). Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenaseexpressing dendritic cells: Mediation of suppression by tryptophan metabolites.J. Exp. Med.196, 447–457.
Munn, D.H.et al.(1998). Prevention of allogeneic fetal rejection by tryptophan catabolism.Science281, 1191–1193.
Mellor, A.L.et al.(2001). Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.Nat. Immunol2(1), 64–68.
Alexander, A.M., M. Crawford, S. Bertera, W.A. Rudert, O. Takikawa, P.D. Robbinset al.(2002). Indoleamine 2,3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes.Diabetes51(2), 356–365.
Grohmann, U.et al.(2002). CTLA-4-Ig regulates tryptophan catabolism in vivo.Nat. Immunol.3(11), 1097–1101.
Salomon, B. and J. Bluestone (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation.Annu. Rev. Immunol.19, 225–252.
Konieczny, B.et al.(1998). IFN-y is critical for long-term allograft survival induced by blocking the CD28 and CD40 ligand T cell costimulation pathways.J. Immunol.160, 2059–2064.
Shinomiya, M.et al.(1999). Transfer of dendritic cells (DCs) ex vivo stimulated with interferon-gamma (IFN-y) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice.Clin. Exp. Immunol.117(1), 38–43.
Sobel, D.et al.(2002). Gamma interferon paradoxically inhibits the development of diabetes in the NOD mouse.J. Autoimmunity19(3), 129–137.
Kaufman, K.et al.(1999). The CTLA-4 gene is expressed in placental fibroblasts.Mol. Hum. Reprod.5(1), 84–87.
Banchereau, J.et al.(2000). Immunobiology of dendritic cells.Annu. Rev. Immunol.18, 767–811.
Bevan, M. (1976). Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming.J. Immunol.117, 2233–2238.
Bevan, M. (1976). Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay.J. Exp. Med.143, 1283–1288.
Albert, M., B. Sauter, and N. Bhardwaj (1998). Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.Nature392, 86–89.
Munz, C.et al.(2000). Human CD4+T lymphocytes consistently respond to latent Epstein-Barr virus nuclear antigen EBNA1.J. Exp. Med.191, 1649–1660.
Kovacsovics-Bankowski, M. and K. Rock (1995). A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules.Science267, 243–246.
Rodriguez, A.et al.(1999). Selective transport of intemalized antigens to the cytosol for MHC class I presentation in dendritic cells.Nat. Cell Biol.1, 362–368.
Svensson, M., B. Stockinger, and M. Wick (1995). Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for major histocompatibility complex class I-restricted epitope presentation.Eur. J. Immunol.25, 1063–1070.
Svensson, M., B. Stockinger, and M. Wick (1997). Bone marrow-derived dendritic cells can process bacteria for MHC-I and MHC-II presentation to T cells.J. Immunol.158, 4229–4236.
Huang, A.et al.(1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.Science264, 961–965.
Zitvogel, L.et al.(1998). Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes.Nat. Med.4, 594–600.
Kurts, C.et al.(1996). Constitutive class I-restricted exogenous presentation of self antigens in vivo.J. Exp. Med.184, 923–930.
Heath, W.R. and F.R. Carbone (2001). Cross-presentation, dendritic cells, tolerance and immunity.Annu. Rev. Immunol.19, 47–64.
Steinman, R.M.et al.(2000). The induction of tolerance by dendritic cells that have captured apoptotic cells.J. Exp. Med.191(3), 411–416.
Urban, B., N. Willcox, and D. Roberts (2001). A role for CD36 in the regulation of dendritic cell function.Proc. Natl. Acad. Sci. USA98, 8750–8755.
Stuart, L.et al.(2002). Inhibitory effects of apoptotic-cell ingestion upon endotoxin-driven myeloid dendriticcell maturation.J. Immunol.168, 1627–1635.
Ohashi, P.et al.(1991). Ablation of “tolerance” and induction of diabetes by virus infection in viral antigen transgenic mice.Cell65, 305–317.
Oldstone, M.et al.(1991). Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response.Cell65, 319–331.
Kurts, C.et al.(1998). Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction..J. Exp. Med.188, 409–414.
Kurts, C.et al.(1999). CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose.Proc. Natl. Acad. Sci. USA96, 12703–12707.
Kovacsovics-Bankowski, M.et al.(1993). Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages.Proc. Natl. Acad. Sci. USA90, 4942–4946.
Yrlid, U. and M.J. Wick (2000). Salmonella-induced apoptosis of infected macrophages results in presentation of a bacteria-encoded antigen after uptake by bystander dendritic cells.J. Exp. Med.191(4), 613–623.
Albert, M.L.et al.(1998). Immature dendritic cells phagocytose apoptotic cells via av135and CD36, and cross-present antigens to cytotoxic T lymphocytes.J. Exp. Med.188(7), 1359–1368.
den Haan, J.M., S.M. Lehar, and M.J. Bevan (2000). CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo.J. Exp. Med.192(12), 1685–1696.
lyoda, T.et al.(2002). The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo.J. Exp. Med.195(10), 1289–1302.
Austyn, J. and R. Steinman (1988). The passenger leukocyte-a fresh look.Transplant. Rev.2, 139–176.
Lechler, R. and J. Batchelor (1982)..Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells.J. Exp. Med.155, 31–41.
Faustman, D. (1984). Prevention of rejection of mutine islet allografts by pretreatment with anti-dendritic cell antibody.Proc. Natl. Acad. Sci. USA81, 3864.
Iwai, H. (1989). Acceptance of mutine thyroid allografts by pretreatment of anti-la or anti-dendritic cell antibody.Transplantation47, 45.
Josien, R.et al.(1998). Critical requirement for graft passenger leukocytes in allograft tolerance induced by donor blood transfusion.Blood92(12), 4539–4544.
Sun, J.et al.(1995). Deletion of spontaneous rat liver allograft acceptance by donor irradiation.Transplantation60(3), 233–236.
Daniel, C., S. Horvath, and P. Allen (1998). A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR.Immunity162, 543–552.
Matzinger, P. and M. Bevan (1977). Hypothesis: Why do so many lymphocytes respond to major histocompatibility antigens?Cell. Immunol.29(1), 1–5.
Suchin, E., A. Wells, and L. Turka (2001). Quantifying the frequency of alloreactive cells in vivo: New answers to an old question.J. Immunol.166, 973–981.
Lechler, R.I., O.A. Garden, and L.A. Turka (2003). The complementary roles of deletion and regulation in transplantation tolerance.Nat. Rev. Immunol.3, 147–158.
Chow, D., V. Saper, and S. Strober (1987). Renal transplant patients treated with total lymphoid irradiation show specific unresponsiveness to donor antigens in the mixed leukocyte reaction (MLR).J. Immunol.138, 3746–3750.
DeBruyne, L., D. Renlund, and D. Bishop (1995). Evidence that human cardiac allograft acceptance is associated with a decrease in donor-reactive helper T lymphocytes.Transplantation59, 778–783.
AL, P.H.E. (1998). Assessment of the contribution that direct allorecognition makes to the progression of chronic cardiac transplant rejection in humans.Circulation97, 1257–1263.
AL, R.B.E. (2001). Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: Implications for the pathogenesis of chronic allograft nephropathy.J. Immunol.167, 7199–7206.
Benichou, G., A. Valujskikh, and P. Heeger (1999). Contributions of direct and indirect T-cell alloreactivity during allograft rejection in mice.J. Immunol.162, 352–358.
Benham, A., G. Sawyer, and J. Fabre (1995). Indirect T-cell allorecognition of donor antigens contributes to the rejection of vascularized kidney allografts.Transplantation59, 1028–1032.
AL, M.B.E. (2001). Acute rejection in the absence of cognate recognition of allograft by T cells.J. Immunol.166, 4879–4883.
Larsen, C.P., P.J. Morris, and J.M. Austyn (1990). Donor dendritic leukocytes migrate from cardiac allografts into recipients’ spleens.Transplant. Proc.22(4), 1943–1944.
Larsen, C.P.et al.(1990). Migration and maturation of Langerhans cells in skin transplants and explants.J. Exp. Med.172(5), 1483–1493.
Sauter, B.et al.(2000). Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells.J. Exp. Med.191, 423–434.
Forster, I. and I. Lieberam (1996). Peripheral tolerance of CD4 T cells following local activation in adolescent mice.Eur. J. Immunol.26, 3194–3202.
Adler, A.et al.(1998). CD4+ tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells.J. Exp. Med.187, 1555–1564.
Morgan, D., H. Kreuwel, and L. Sherman (1999). Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens.J. Immunol.163, 723–727.
Pooley, J.L., W.R. Heath, and K. Shortman (2001). Cutting edge: Intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells.J. Immunol.166(9), 5327–5330.
Jonuleit, H.et al.(2000). Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells.J. Exp. Med.192(9), 1213–1222.
Dhodapkar, M.V.et al.(2001). Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells.J. Exp. Med.193(2), 233–238.
Dhodapkar, M.V. and R.M. Steinman (2002). Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans.Blood100(1), 174–177.
Fu, Eet al.(1996). Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients.Transplantation62(5), 659–665.
Fu, F.et al.(1997). Costimulatory molecule-deficient dendritic cell progenitors induce T cell hyporesponsiveness in vitro and prolong the survival of vascularized cardiac allografts.Transplant. Proc.29(1–2), 1310.
DePaz, H.et al.(2003). Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophage-colony stimulating factor prolong donor-specific rat cardiac allograft survival.Transplantation75(4), 521–528.
James, E.et al.(2002). HY peptides modulate transplantation responses to skin allografts.Int. Immunol.14(11), 1333–1342.
Lu, L. and A.W. Thomson (2002). Manipulation of dendritic cells for tolerance induction in transplantation and autoimmune disease.Transplantation73(1 Suppl), S19–S22.
Lu, L.et al.(1997). Blockade of the CD40–CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.Transplantation64(12), CD40–CD40.
Steinbrink, K.et al.(1997). Induction of tolerance by IL-10-treated dendritic cells.J. Immunol.159, 4772.
Nouri-Shirazi, M. and E. Guinet (2002). Direct and indirect cross-tolerance of alloreactive T cells by dendritic cells retained in the immature stage.Transplantation74(7), 1035–1044.
Szabo, G., C. Gavala, and P. Mandrekar (2001). Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells.J. Invest. Med.49, 442.
Satake, Y.et al.(2000). Characterization of rat OX40 ligand by monoclonal antibody.Biochim. Biophys. Acta270, 1041.
Yuan, X.et al.(2003). The role of the CD134–CD134 ligand costimulatory pathway in alloimmune responses in vivo.J. Immunol.170, CD134–CD134.
Dupuy, P.et al.(1991). Cyclosporin A inhibits the antigen-presenting functions of freshly isolated human Langerhans cells in vitro.J. Invest. Dermatol.96(4), 408–413.
Griffin, M.D.et al.(2001). Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo.Proc. Natl. Acad. Sci. USA98(12), 6800–6805.
Piemonti, L., P. Monti, and M.S.E. AL (2000). Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells.J. Immunol.164, 4443.
Clavreul, A., C. D’Hellencourt, and C. Montero-Menei (1998). Vitamin D differentially regulates B7.1 and B7.2 expression on human peripheral blood monocytes.Immunology95, 272.
Terada, N., J. Lucas, and A.S.E. AL (1993). Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cell cycle.J. Cell Physiol.154, 7.
Aagaard-Tillery, K. and D. Jelinek (1994). Inhibition of B lymphocyte cell cycle progression and differentiation by rapamycin.Cell. Immunol.156, 493.
Taylor-Fishwick, M. Kahan, and P.H.E. AL, (1993). Evidence that rapamycin has differential effect on IL-4 function.Transplantation56, 368.
Monti, P.et al.(2003). Rapamycin impairs antigen uptake of human dendritic cells.Transplantation75(1), 137–145.
Vosters, O.et al.(2003). Dendritic cells exposed to nacystelyn are refractory to maturation and promote the emergence of alloreactive T cells.Transplantation75(3), 383–389.
Giannoukakis, N.et al.(2000). Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides.Mol. Ther.1(5 Pt 1), 430–437.
Krasinskas, A.et al.(2000). Replacement of graft-resident donor-type antigen presenting cells alters the tempo and pathogenesis of murine cardiac allograft rejection.Transplantation70, 514–521.
Wise, M.et al.(1998). Cutting edge: Linked suppression of skin graft rejection can operate through indirect recognition.J. Immunol161, 5813–5816.
Nimi, M.et al.(2001). Oral antigen induces allograft survival by linked suppression via the indirect pathway.Transplant. Proc.33, 81.
Matsue, H.et al.(1999). Induction of antigen-specific immunosuppression by CD95L cDNA-transfected “killer” dendritic cells.Nat. Med.5(8), 930–937.
Lu, L.et al.(1999). Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients.Gene Ther.6(4), 554–563.
O’Rourke, R.W.et al.(2000). A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival.Transplantation69(7), 1440–1446.
Takayama, T.et al.(2002). Retroviral delivery of transforming growth factor-betal to myeloid dendritic cells: Inhibition of T-cell priming ability and influence on allograft survival.Transplantation74(1), 112–119.
Buonocore, S.et al.(2002). Dendritic cells transduced with viral interleukin 10 or Fas ligand: No evidence for induction of allotolerance in vivo.Transplantation73(1), S27–S30.
Muller, A., M. Rafter, and G. Schonrich (1999). T cell stimulation upon long-term secretion of viral IL-10.J. Immunol.29, 2740.
Buonocore, S.et al.(2003). Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo.Blood101(4), 1469–1476.
Gershon, R.et al.(1972). Suppressor T cells..J. Immunol.108, 586–590.
Sakaguchi, S.et al.(1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.J. Immunol.155, 1151–1164.
AL, K.S.E. (2001). Requirement for natural killer T (NKT) cells in the induction of allograft tolerance.Proc. Natl. Acad. Sci. USA98, 2577–2581.
AL, L.G.E. (2002). Both CD4+CD25+ and CD4+CD25- regulatory cells mediate dominant transplantation tolerance.J. Immunol.168, 5558–5565.
Jordan, M.et al.(2001). Thymic selection of CD4+CD25 + regulatory T cells induced by an agonist self-peptide.Nat. Immunol.2, 301.
Mahnke, K.et al.(2002). Immature, but not inactive: The tolerogenic function of immature dendritic cells.Immunol. Cell Biol.80, 477.
Steinman, R.M. and M.C. Nussenzweig (2002). Avoiding honor autotoxicus: The importance of dendritic cells in peripheral T cell tolerance.Proc. Natl. Acad. Sci. USA99(1), 351–358.
Dieckmann, D.et al.(2002). Human CD4+CD25+ regulatory, contact-dependent T cells induce interleukin-lproducing, contact-independent type- 1-like regulatory T cells.J. Exp. Med.196, 247–253.
Hori, S., T. Monura, and S. Sakaguchi (2003). Control of regulatory T cell development by the transcription factor Foxp3.Science299, 1057–1061.
Thomas, J.M.et al.(1999). Peritransplant tolerance induction in macaques: Early events reflecting the unique synergy between immunotoxin and deoxyspergualin.Transplantation68(11), 1660–1673.
Luke, P.et al.(2001). Anti-CD45RB monoclonal antibody-mediated transplantation tolerance.Curr. Mol. Med.1, 533.
Min, W.-P.et al.(2003). Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance.J. Immunol.170, 1304–1312.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Swanson, K.A., Wilkes, D.S. (2004). Dendritic Cells in Transplantation: Origin, Immune Activation, and Allograft Tolerance. In: Wilkes, D.S., Burlingham, W.J. (eds) Immunobiology of Organ Transplantation. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-8999-4_12
Download citation
DOI: https://doi.org/10.1007/978-1-4419-8999-4_12
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-4754-5
Online ISBN: 978-1-4419-8999-4
eBook Packages: Springer Book Archive